The neurodegenerative disease startup has emerged from stealth with $30m taken in a series A round co-led by GlaxoSmithKline's SR One unit.
SR One, the corporate venturing arm of pharmaceutical firm GlaxoSmithKline, has co-led a $30m series A round for US-based immuno-neurology therapy developer Tranquis Therapeutics.
The round was co-led by venture capital firm Remiges Ventures and also featured Vivo Capital, Hillsborough Venture, Correlation Ventures and undisclosed other investors.
Tranquis is working on treatments for neurodegenerative and ageing-related diseases triggered by dysfunction in myeloid immune cells. The approach could herald treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease and…
